Human papilloma virus (HPV) prophylactic vaccination: Challenges for public health and implications for screening

Vaccine

Volumn 25, Issue 16 SPEC. ISS., 2007, Pages 3007-3013

  Adams, M ^a   Jasani, B ^b   Fiander, A ^b  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

HPV vaccination; Implications; Public health

Indexed keywords

WART VIRUS VACCINE;

ANXIETY; ARTICLE; CLINICAL TRIAL; COMMERCIAL PHENOMENA; HUMAN; MORBIDITY; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNITED KINGDOM; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; VERRUCA VULGARIS; WART VIRUS;

EID: 33947596421     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.016     Document Type: Article

References (32)

1. Bosch F.X., Lorincz A., Munoz N., Meijer C.J.M., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 (2002) 244-265
2. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Guilano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase 11 efficacy trial. Lancet Oncol 6 5 (2005) 271-278
3. Harper D., Franco E., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
4. Peto J., Gilham C., Fletcher O., and Mathews F.E. The cervical cancer epidemic that screening prevented in the UK. Lancet 364 9430 (2004) 249-256
5. Nanda K., McCrory D.C., Myers E.R., Bastian L.A., Hasselblad V., Hickey J.D., et al. Accuracy of the Papanincolaou test in screening for and follow up of cervical cytologic abnormalities: a systematic review. Ann Int Med 132 (2000) 810-819
6. Sasieni P., Adams J., and Cuzick J. Benefit of cervical screening at different ages: evidence from UK audit of screening histories. Br J Cancer 89 (2003) 88-93
7. Benard V.B., Eheman C.R., Lawson H.W., Blackman D.K., Anderson C., Helsel W., et al. Cervical screening in the National Breast and Cervical Cancer Early Detection Program 1995-201. Obstet Gynecol 103 (2004) 564-571
8. Office of National Statistics Cervical Cancer Screening Programme. England 2004-2005.
9. Cervical Screening Wales Annual Report 2005.
10. Gray N.M., Sharp L., Cotton S.C., Mason L.F., Little J., Walker L.G., et al. Psychological effects of low grade abnormal cervical smear test result: anxiety and associated factors. Br J Cancer 94 (2006) 1253-1263
11. NHS Health & Social Care Information Centre. Community Health Services Statistics website: http://www.cnhs.uk/.
12. Krane J.F., Ganter S.R., Trask C.E., Hogan C.L., and Lee K.R. Papanicololaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer 93 (2001) 8-15
13. Raab S.S. Can glandular lesions be diagnosed in pap smear cytology?. Diagn Cytopathol 23 (2000) 127-133
14. Bulk S., Visser O., Roendaal L., Verheijen R.H., and Meijer C.J. Cervical cancer in the Netherlands 1989-1998: decrease of squamous carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 1134 (2005) 1005-1009
15. Harper D.M., Franco E.L., Wheeler C.M., Mosicki A.B., Romanowski B., Rotelli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow up from a randomised control trial. Lancet 367 (2006) 1247
16. Vogel F.R. Improving vaccine performance with adjuvants. Clin Infect Dis 30 Suppl. 3 (2000) 469-475
17. Stanberry L.R., Spruance S.L., and Cunningham A.L. Glycoprotein-d-adjuvant vaccine to prevent genital herpes. N Engl J Med 347 (2002) 1652-1661
18. Munoz N. Review of the initial phase 3 clinical data for the quadrivalent human papilloma virus vaccine. 6th international multidisciplinary congress of the European research organization on genital infection and neoplasia (EUROGIN). Paris (2006)
19. Koutsky L.A., and Harper D.M. Current findings from prophylactic HPV vaccine trials. Vaccine 24S3 (2006) 114-121
20. Munoz N., Bosch F.X., Castellsaque X., Diaz M., de Sanjose S., Hamouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
21. Clifford G.M., Gallus S., Herero R., Munoz N., Snijders P.J., Vacarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 (2005) 991-998
22. Clifford G.M., Ran R.K., Franceschi S., Smith J.S., Gough G., Pimenta J.M., et al. Human papilloma virus genotype distribution in low grade lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 278-285
23. Hagensee M.E., Yaegashi N., and Galloway D.A. Self assembly of human papillomavirus type 1 capsids by expression of the LI protein alone or by coexpression of the LI and L2 capsid proteins. J Virol 67 (1993) 315-322
24. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papilloma virus vaccination programs. Emerg Infect Dis 10 (2004) 1915-1923
25. Kohli M., Ferko N., Martin A., Franco E.L., Jenkins D., Gallivan S., Sherlaw-Johnson C., and Drummond M. Estimating the long term impact of a prophylactic human papilloma virus (HPV) 16/18 vaccine on the burden of cervical disease in the UK. 2006 poster P-200 23rd international papilloma conference and clinical workshop. Prague (2006)
26. Moscicki A.B., Schiffman M., Kjaer S., and Villa L.L. Updating natural history of HPV and anogenital cancer. Vaccine 24S3 (2006) S3/42-S3/51
27. Wright T.C., Van Damme P., Schmitt H.J., and Meheus A. HPV vaccine introduction in industrialised countries. Vaccine 24S3 (2006) S3/122-S3/131
28. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomised controlled trial. Obstet Gynecol 107 (2006) 18-27
29. Zimet G.D., Liddon N., Rosenthal S.L., Lazcano-Ponce E., and Allen B. Psychosocial aspects of vaccine acceptability. Vaccine 24S3 (2006) 201-209
30. Brabin L., Roberts S.A., Farzaneh F., and Kitchener H.C. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine 24 16 (2006) 3087-3094
31. Bramley J.C., Wallace L.A., Ahmed S., Duff R., Carman W.F., Cameron S.O., et al. Universal hepatitis B vaccination of UK adolescents a feasibility acceptability study. Commun Dis Public Health 5 4 (2002) 318-320
32. Franco E.L., Cuzick J., Hildesheim A., and de Sanjosé S. Issues in planning cervical screening in the era of HPV vaccination. Vaccine 24S3 (2006) S3/171-S3/177